Table 2 Details of systemic therapy before RFA treatment
Regimen | Line of therapy and regimen administered | Response to last line therapy regimen1 | |||||
|---|---|---|---|---|---|---|---|
1st line | 2nd line | 3rd line | Last line2 | PR | SD | PD | |
5-FU, n | 30 | 5 | 0 | 17 | 10 | 3 | 4 |
5-FU + Bevacizumab, n | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
FOLFOX, n (%) | 31 | 19 | 2 | 35 (40) | 20 | 5 | 10 |
FOLFOX + Bevacicumab, n | 1 | 0 | 1 | 2 | 1 | 1 | 0 |
FOLFOX + Cetuximab, n | 3 | 2 | 0 | 5 | 3 | 1 | 1 |
FOLFIRI, n (%) | 18 | 12 | 1 | 20 (23) | 10 | 1 | 9 |
FOLFIRI + Bevacizumab, n | 3 | 4 | 3 | 8 | 3 | 3 | 2 |
FOLFIRI + Cetuximab, n | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total number (%) | 88 (100) | 40 (45) | 8 (9) | 88 (100) | 49 | 13 | 26 |